cap-dependent

Cap-dependent endonuclease-IN-1 is a highly potent, orally active cap-dependent endonuclease inhibitor with antiviral activity for studying influenza virus infection.

Cap-dependent endonuclease-IN-26, a potent inhibitor of cap-dependent endonuclease (CEN) with an IC50 of 286 nM, exhibits significant antiviral activity against a broad spectrum of influenza A and B strains [1].

Cap-dependent endonuclease-IN-25 is a macrocyclic pyridoxal derivative and a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) with potential for studying viral infections caused by viruses of the Orthomyxoviridae family.

Cap-dependent endonuclease-IN-6 (compound 13) is a Cap-dependent endonuclease (CEN) inhibitor that targets and inhibits the influenza virus.

Cap-dependent endonuclease-IN-19, a spirocyclic pyridinone derivative, is a potent inhibitor of cap-dependent nucleic acid endonuclease (CEN) and effectively inhibits the RNA polymerase activity of influenza A virus.

Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN) and demonstrates research potential against influenza virus infection [influenza A only].

Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN), effectively inhibiting influenza viruses with low cytotoxicity, good in vivo pharmacokinetic and pharmacodynamic properties, and good hepatic microsomal stability. It has shown investigational potential against viral infections, including influenza A, B, and C.

Cap-dependent endonuclease-IN-11 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) with demonstrated research potential for treating viral infections.

Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) and demonstrates inhibitory effects on influenza virus replication, showing research potential against influenza virus infection (influenza A).

Cap-dependent endonuclease-IN-23 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) and effectively inhibits influenza virus replication, demonstrating significant research potential for influenza virus infection (influenza A).

Cap-dependent endonuclease-IN-5 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) with significant influenza virus inhibitory activity, demonstrating lower cytotoxicity and improved in vivo pharmacokinetic and pharmacodynamic properties.

Cap-dependent endonuclease-IN-14 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) and can inhibit the replication of influenza viruses, showing potential for treating viral infections caused by influenza viruses.

Cap-dependent endonuclease-IN-17, a cap-dependent endonuclease (CEN) inhibitor, exhibits antiviral activity against influenza virus A Hanfang 359 95 (H3N2) with an IC50 of 1.29 μM.

Cap-dependent endonuclease-IN-8 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) that effectively inhibits the replication of orthomyxoviruses, including influenza A, B, and C.

Cap-dependent endonuclease-IN-16, a pyridone polycyclic derivative, is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) with potential applications in influenza studies.

Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) and significantly inhibits influenza A virus RNA polymerase activity.

Cap-dependent endonuclease-IN-3 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN), demonstrating potential for investigating influenza A and B infections.

Cap-dependent endonuclease-IN-15 is a potent inhibitor of cap-dependent endonuclease (CEN), effectively hindering the replication of influenza virus and showing promise for investigating viral infections triggered by influenza viruses.

Cap-dependent endonuclease-IN-7 is a potent inhibitor of cap-dependent endonuclease (CEN), effectively inhibiting viral mRNA synthesis and halting virus proliferation, making it especially promising for research into viral infections, including influenza types A, B, and C.

Cap-dependent endonuclease-IN-9 is a potent cap-dependent endonuclease (CEN) inhibitor with notable efficacy against the influenza virus, minimal cytotoxicity, enhanced in vivo pharmacokinetics, and robust pharmacodynamics. It effectively suppresses the RNA polymerase activity of Influenza A virus[1].

Cap-dependent Endonuclease-IN-12 (EXP-35) is a potent inhibitor of Cap-dependent endonuclease, demonstrating low cytotoxicity. This compound exhibits inhibitory effects on H1N1 [1].

Cap-dependent endonuclease-IN-22 is a potent inhibitor of cap-dependent endonuclease (CEN) [1].

Baloxavir (S-033447) is a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.

Baloxavir marboxil (S-033188) is a novel cap-dependent endonuclease inhibitor designed for the treatment of influenza A and B virus infections.